Britain and America have signed a significant trade agreement that will maintain no levies on British medicine exports being sold in the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has pledged to boost expenditure on pharmaceuticals through the National Health Service (NHS). This pledge guarantees that tariffs on these crucial exports will be held at nothing for a duration of three years.
This agreement is in response to recent threats to significantly raise duties on branded pharmaceutical imports, with potential rates discussed up to 100%.
"This agreement with the United Kingdom reinforces the international landscape for new treatments and brings long-overdue equity to transatlantic medicine commerce," a release declared.
Economic Impact
Pharmaceuticals are one of the Britain's largest exports to the America, which is clearly the primary market for major British pharmaceutical firms.
Export figures reveal that in the 12 months prior to last September, the UK exported medicines worth £11.1bn to the US. This amount made up nearly one-fifth of British export trade in that span.
"This deal safeguards employment, boosts capital expenditure and sets the stage for the UK to establish itself as a global hub for biotech and pharma," a government official remarked.
Key UK Commitments
The pact includes several specific pledges from the UK:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new treatments to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a goal to raise total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Payback Limit: The percentage drug companies must pay back to the NHS to stay within budget will be capped at fifteen percent. Last year, repayments exceeded 20%.
Broader Context
The pact comes amid a ongoing tension between the drug companies and the British authorities over spending levels and approval rates.
These tensions were heightened by claims that American patients were charged significantly more for the equivalent treatments than patients in the Britain and the EU.
Recently, several major drug company projects in the UK have been halted or scrapped, while major expansions have been directed toward American operations.
A senior figure stated that the NHS needed to spend more on drugs, noting that its spending on drugs had shrunk as a percentage of its total funding over the last ten years.
